OphtAI-Eval: is a prospective, multicentre, post-marketing clinical follow-up study (SCAC) of diagnostic validation (comparative vs gold standard).~It aims to: validate the diagnostic performance of the OphtAI software for the automated screening of diabetic retinopathy, diabetic macular edema, glaucoma, ARM and AMD.~Evolucare OphtAI is a medical imaging console for ophthalmology, interfaced with Evolucare Imaging.~It allows the detection, by statistical learning algorithms, of the following ocular pathologies using photographs of the retina:~Diabetic retinopathy (DR) (including gradation),~Diabetic macular edema (DME)~Age-related macular degeneration (AMD)~Age-related maculopathy (ARM, early form of AMD),~Glaucoma.~Evolucare OphtAI, is available on the French market since March 2019.
Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through the OphtAI-EVAL.